Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2013 Dec 6;113(12):1275-7.
doi: 10.1161/CIRCRESAHA.113.302667.

High-density lipoprotein: NO failure in heart failure

Ali Javaheri  1 , Daniel J Rader
Affiliations
Editorial

High-density lipoprotein: NO failure in heart failure

Ali Javaheri et al. Circ Res. .
No abstract available

PubMed Disclaimer

Figures

Figure
Figure. Healthy high-density lipoprotein (HDL) and HDL containing sphingosine 1-phosphate (S1P) promote nitric oxide (NO) production through activation of scavenger receptor B1 (SR-BI) and S1PR3 receptor
Dysfunctional HDL rich in malondialdehyde (MDA) and symmetrical dimethylarginine (SDMA) decreases NO production via activation of lectin-like oxidized LDL receptor-1 (LOX-1) or Toll-like receptor-2 (TLR-2). eNOS indicates endothelial nitric oxide synthase; PI3K, phosphoinositide-3 kinase; and PKC-βII, protein kinase C βII.
See this image and copyright information in PMC

Comment on

References

    1. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8–15. - PubMed
    1. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis. 1988;8:737–741. - PubMed
    1. Abbott RD, Wilson PW, Kannel WB, Castelli WP. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis. 1988;8:207–211. - PubMed
    1. HPS2-THRIVE Collaborative Group. Hps2-thrive randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279–1291. - PMC - PubMed
    1. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267. - PubMed

Substances